Intriguingly, data from patients with heart failure demonstrates the beneficial effect of dapagliflozin is preserved amongst patients with high baseline plasma ET-1 levels and treatment resulted in a modest reduction in plasma ET-1 after 12 months. This evidence concerns the gene EDN1 and heart failure.